Cogent Biosciences (COGT)
(Real Time Quote from BATS)
$6.82 USD
+0.32 (4.92%)
Updated May 1, 2024 01:44 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
COGT 6.82 +0.32(4.92%)
Will COGT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for COGT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for COGT
Does Cogent Biosciences, Inc. (COGT) Have the Potential to Rally 78.9% as Wall Street Analysts Expect?
Cogent Biosciences, Inc. (COGT) Is a Great Choice for "Trend" Investors, Here's Why
COGT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 66% Upside in Cogent Biosciences, Inc. (COGT): Can the Stock Really Move This High?
Here's What Could Help Cogent Biosciences, Inc. (COGT) Maintain Its Recent Price Strength
Biotech Stock Roundup: BLUE Up on Regulatory Updates, RIGL's Pipeline News & More
Other News for COGT
Cogent Biosciences: A Strong Buy on Oncology Asset Potential and Favorable Market Dynamics
Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
Cogent Biosciences presents preclinical data of CNS-penetrant ErbB2 inhibitor
Commit To Buy Cogent Biosciences At $5, Earn 21.4% Annualized Using Options